MX369550B - Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo. - Google Patents
Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.Info
- Publication number
- MX369550B MX369550B MX2015003744A MX2015003744A MX369550B MX 369550 B MX369550 B MX 369550B MX 2015003744 A MX2015003744 A MX 2015003744A MX 2015003744 A MX2015003744 A MX 2015003744A MX 369550 B MX369550 B MX 369550B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- fusion gene
- drug targeting
- pharmaceutical drug
- fgfr
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
La presente invención se refiere al gen que codifica para FGFR con respecto a su expresión, hiperamplificación, mutación, translocación o similares en diversas células cancerosas, como un resultado, se identificaron y aislaron polipéptidos de fusión novedosos en los cuales el polipéptido FGFR3 está fusionado con un polipéptido diferente, a partir de diversos tipos de células derivadas de cáncer de vejiga y células de cáncer de pulmón. El uso de un polipéptido de fusión de la presente invención como un biomarcador en un tratamiento contra el cáncer basado en inhibidor de FGFR permite evitar los efectos secundarios en el tratamiento contra el cáncer y controlar la condición terapéutica para producir el mejor efecto terapéutico y de esta manera se habilita medicina individualizada.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012214739 | 2012-09-27 | ||
JP2013149217 | 2013-07-18 | ||
PCT/JP2013/076200 WO2014051022A1 (ja) | 2012-09-27 | 2013-09-27 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015003744A MX2015003744A (es) | 2015-06-24 |
MX369550B true MX369550B (es) | 2019-11-12 |
Family
ID=50388416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003744A MX369550B (es) | 2012-09-27 | 2013-09-27 | Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo. |
Country Status (15)
Country | Link |
---|---|
US (2) | US10689705B2 (es) |
EP (1) | EP2902489B9 (es) |
JP (2) | JP6117222B2 (es) |
KR (1) | KR101942148B1 (es) |
CN (2) | CN104797710A (es) |
AU (1) | AU2013320972B2 (es) |
CA (1) | CA2886002C (es) |
EA (1) | EA031631B1 (es) |
ES (1) | ES2643571T3 (es) |
HK (2) | HK1210500A1 (es) |
MX (1) | MX369550B (es) |
RU (1) | RU2673943C2 (es) |
SG (1) | SG11201502455TA (es) |
TW (1) | TWI606066B (es) |
WO (1) | WO2014051022A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013133351A1 (ja) | 2012-03-08 | 2013-09-12 | アステラス製薬株式会社 | 新規fgfr3融合体 |
EA031631B1 (ru) | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
AU2013337264B2 (en) * | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
TW201609093A (zh) | 2013-12-27 | 2016-03-16 | Chugai Pharmaceutical Co Ltd | Fgfr門控蛋白變異基因及以其爲標的之醫藥 |
SI3122358T1 (sl) | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka |
ES2914072T3 (es) | 2014-08-18 | 2022-06-07 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monocíclico y su cristal |
US20160090633A1 (en) * | 2014-09-26 | 2016-03-31 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US10479780B2 (en) | 2015-06-17 | 2019-11-19 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivatives |
CN105368861B (zh) * | 2015-11-23 | 2018-11-09 | 上海交通大学医学院附属瑞金医院 | 一种fgfr3突变体的重组表达载体及其构建方法和应用 |
CN115515248A (zh) | 2016-08-11 | 2022-12-23 | 弗劳恩霍夫应用研究促进协会 | 利用缩短帧结构的探测反馈 |
CN111712245A (zh) | 2018-03-28 | 2020-09-25 | 卫材R&D管理有限公司 | 用于肝细胞癌的治疗剂 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH642458A5 (en) | 1980-04-25 | 1984-04-13 | Hoffmann La Roche | Immunological method |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | 組換え結合タンパク質およびペプチド |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0962467A4 (en) | 1996-09-26 | 2002-10-30 | Chugai Pharmaceutical Co Ltd | ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
DE60233509D1 (de) | 2001-06-20 | 2009-10-08 | Fibron Ltd | Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
ATE437963T1 (de) | 2003-03-26 | 2009-08-15 | Progenika Biopharma Sa | In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase |
IL156495A0 (en) * | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
EP1692085A4 (en) | 2003-11-07 | 2010-10-13 | Novartis Vaccines & Diagnostic | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA |
US7745437B2 (en) * | 2004-06-10 | 2010-06-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
AU2006272759B2 (en) | 2005-07-22 | 2012-01-12 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
US8158360B2 (en) * | 2005-12-08 | 2012-04-17 | Novartis Ag | Effects of inhibitors of FGFR3 on gene transcription |
CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
TW200811134A (en) * | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009014565A2 (en) | 2007-04-26 | 2009-01-29 | Ludwig Institute For Cancer Research, Ltd. | Methods for diagnosing and treating astrocytomas |
JPWO2009113436A1 (ja) | 2008-03-14 | 2011-07-21 | 国立大学法人 千葉大学 | Fgfr3遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法 |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
SI3702371T1 (sl) * | 2009-03-25 | 2023-01-31 | Genentech, Inc. | Protitelesa proti FGFR3 in postopki za uporabo le-teh |
CA2770195C (en) * | 2009-08-07 | 2015-10-13 | Chugai Seiyaku Kabushiki Kaisha | Aminopyrazole derivative |
JP5620417B2 (ja) * | 2011-02-07 | 2014-11-05 | 中外製薬株式会社 | アミノピラゾール誘導体を含む医薬 |
CN103443361A (zh) | 2011-03-28 | 2013-12-11 | 大金工业株式会社 | 防水生生物附着片材和防水生生物附着涂料 |
EP2761300A4 (en) | 2011-09-27 | 2015-12-02 | Univ Michigan | FUSIONS OF RECURRENT GENES IN BREAST CANCER |
JP2013149217A (ja) | 2012-01-23 | 2013-08-01 | Toshiba Corp | 改札機、駅務機器、及び制御方法 |
KR102032007B1 (ko) | 2012-02-28 | 2019-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 질소 함유 방향족 헤테로환 화합물 |
WO2013133351A1 (ja) | 2012-03-08 | 2013-09-12 | アステラス製薬株式会社 | 新規fgfr3融合体 |
WO2014018673A2 (en) | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
EA031631B1 (ru) * | 2012-09-27 | 2019-01-31 | Чугаи Сеияку Кабушики Каиша | Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения |
SG10201808565QA (en) | 2014-03-31 | 2018-11-29 | Debiopharm Int Sa | Fgfr fusions |
US20160090633A1 (en) | 2014-09-26 | 2016-03-31 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
CN107406431B (zh) | 2015-08-20 | 2020-06-26 | 上海昂睿医药技术有限公司 | 吲哚类衍生物及其制备方法和其在医药上的用途 |
-
2013
- 2013-09-27 EA EA201500334A patent/EA031631B1/ru not_active IP Right Cessation
- 2013-09-27 MX MX2015003744A patent/MX369550B/es active IP Right Grant
- 2013-09-27 TW TW102134949A patent/TWI606066B/zh not_active IP Right Cessation
- 2013-09-27 WO PCT/JP2013/076200 patent/WO2014051022A1/ja active Application Filing
- 2013-09-27 CA CA2886002A patent/CA2886002C/en not_active Expired - Fee Related
- 2013-09-27 AU AU2013320972A patent/AU2013320972B2/en not_active Ceased
- 2013-09-27 CN CN201380061499.0A patent/CN104797710A/zh active Pending
- 2013-09-27 CN CN201710831517.9A patent/CN107501413A/zh active Pending
- 2013-09-27 SG SG11201502455TA patent/SG11201502455TA/en unknown
- 2013-09-27 ES ES13842962.6T patent/ES2643571T3/es active Active
- 2013-09-27 US US14/380,399 patent/US10689705B2/en active Active
- 2013-09-27 KR KR1020157010537A patent/KR101942148B1/ko active IP Right Grant
- 2013-09-27 EP EP13842962.6A patent/EP2902489B9/en active Active
- 2013-09-27 JP JP2014538612A patent/JP6117222B2/ja active Active
- 2013-09-27 RU RU2015114616A patent/RU2673943C2/ru active
-
2015
- 2015-07-09 JP JP2015137541A patent/JP2015231377A/ja active Pending
- 2015-11-16 HK HK15111263.0A patent/HK1210500A1/xx unknown
- 2015-11-16 HK HK18103128.9A patent/HK1243718A1/zh unknown
-
2020
- 2020-05-13 US US15/930,648 patent/US20200385812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2886002C (en) | 2020-06-09 |
CN107501413A (zh) | 2017-12-22 |
JP2015231377A (ja) | 2015-12-24 |
WO2014051022A1 (ja) | 2014-04-03 |
EP2902489A1 (en) | 2015-08-05 |
HK1210500A1 (en) | 2016-04-22 |
TW201418284A (zh) | 2014-05-16 |
JPWO2014051022A1 (ja) | 2016-08-22 |
AU2013320972A1 (en) | 2015-04-16 |
EA031631B1 (ru) | 2019-01-31 |
EA201500334A1 (ru) | 2016-01-29 |
JP6117222B2 (ja) | 2017-04-19 |
EP2902489B1 (en) | 2017-09-13 |
MX2015003744A (es) | 2015-06-24 |
EP2902489A4 (en) | 2015-10-21 |
US20150307945A1 (en) | 2015-10-29 |
US20200385812A1 (en) | 2020-12-10 |
RU2015114616A (ru) | 2016-11-20 |
HK1243718A1 (zh) | 2018-07-20 |
US10689705B2 (en) | 2020-06-23 |
RU2673943C2 (ru) | 2018-12-03 |
AU2013320972B2 (en) | 2018-08-30 |
KR101942148B1 (ko) | 2019-01-24 |
EP2902489B9 (en) | 2018-02-07 |
ES2643571T3 (es) | 2017-11-23 |
KR20150060875A (ko) | 2015-06-03 |
SG11201502455TA (en) | 2015-05-28 |
CN104797710A (zh) | 2015-07-22 |
TWI606066B (zh) | 2017-11-21 |
CA2886002A1 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369550B (es) | Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo. | |
TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
MX2021003858A (es) | Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma. | |
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
MX2019007057A (es) | Composiciones de adenovirus. | |
MX2016003945A (es) | Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias. | |
MX346923B (es) | Genes y proteinas para sintesis de alcanoil-coa. | |
WO2012061683A3 (en) | Methods for treating cancer | |
MX2016013025A (es) | Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3. | |
WO2013045707A3 (en) | Biological materials related to c-met | |
IN2014MN01945A (es) | ||
EP3998341A3 (en) | Adenoviral vectors | |
IN2014CN04734A (es) | ||
IN2014MN01944A (es) | ||
WO2012109233A3 (en) | Methods for predicting recurrence risk in breast cancer patients | |
MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
EP2998742A4 (en) | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased | |
NZ704554A (en) | Combination therapy of a smac mimetic and gm-csf | |
WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
AU2014339977A8 (en) | Methods of determining breast cancer prognosis | |
WO2015177775A3 (en) | Nanoparticle gene system with apoptotic effect with tumor specificity for cancer therapy | |
EA201992441A1 (ru) | Способы лечения с использованием аденовируса |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |